SCHEMBL20239192

SCHEMBL20239192

CCc1cnc(NCc2cc(Oc3ccc(CCNC(=O)O)cc3)nc(C)n2)nc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 6/20 0.40
OPRD1 P41143 6/20 0.40
OPRK1 P41145 4/20 0.40
DGAT2 Q96PD7 1/20 0.39
ACACB O00763 1/20 0.39
GLA P06280 2/20 0.38
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
PLAAT3 P53816 2/20 0.37
PLAAT5 Q96KN8 2/20 0.37
PLAAT2 Q9NWW9 2/20 0.37
PLAAT4 Q9UL19 2/20 0.37
EPHX2 P34913 1/20 0.37
GRIN2D O15399 1/20 0.37
GRIN3B O60391 1/20 0.37
SLC6A2 P23975 1/20 0.37
SLC6A3 Q01959 1/20 0.37
GRIN1 Q05586 1/20 0.37
KCNH2 Q12809 1/20 0.37
GRIN2A Q12879 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20239241 0.93 ACACB (0.44) OPRM1OPRD1OPRK1DGAT2ACACB
SCHEMBL20239173 0.91 SMN1; SMN2 (0.46) OPRM1OPRD1OPRK1DGAT2ACACB
SCHEMBL20239244 0.90 DGAT2 (0.48) OPRM1OPRD1OPRK1DGAT2ACACB
SCHEMBL20259256 0.89 IGF1R (0.37) OPRM1OPRD1OPRK1DGAT2GLA
SCHEMBL20239175 0.86 DGAT2 (0.42) OPRM1OPRD1OPRK1DGAT2GLA
SCHEMBL20259074 0.85 DGAT2 (0.41) DGAT2GLAALDH1A1LMNAGRIN1
SCHEMBL20239232 0.84 DGAT2 (0.46) OPRM1OPRD1OPRK1DGAT2ACACB
SCHEMBL20259192 0.84 DGAT2 (0.47) DGAT2ACACBGLAALDH1A1LMNA
SCHEMBL20239151 0.83 SMN1; SMN2 (0.45) OPRM1OPRD1OPRK1DGAT2ACACB
SCHEMBL20239167 0.81 SMN1; SMN2 (0.49) ACACBGLAALDH1A1LMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3298001-B1 DGAT2 INHIBITORS LILLY CO ELI (US) 2020-05-13 EP disclosed
US-10053429-B2 DGAT2 inhibitors ELI LILLY AND COMPANY (US) 2018-08-21 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162825-A1 NOVEL DGAT2 INHIBITORS DGAT2, DGAT1, LCAT OPRM1 4494/4885OPRD1 3481/4885OPRK1 4096/4885
US-10053429-B2 DGAT2 inhibitors DGAT2, DGAT1, LCAT OPRM1 4206/4885OPRD1 3257/4885OPRK1 3822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.